NL-OMON48710已完成不适用
Axonics SacRal NeuromodulaTIon System for UrinAry Urgency Incontinence TreatmeNt - ARTISAN-SNM
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Diagnosis of UUI demonstrated on a 72-hour voiding diary defined as:
- •* a minimum of four (4) leaking episodes associated with urgency,
- •* at least 50% of all leaking episodes associated with urgency, and
- •* at least one leaking episode each 24-hour period. ;Greater than or equal to 6 months* history of UUI diagnosis;For male subjects only:
- •* Peak flow rate > 15 cc/s as verified by uroflowmetry within 6 months prior to enrollment
- •* Residual bladder volume < 150 cc tested within 6 months prior to enrollment;Positive motor response on at least two (2) implanted electrodes during intraoperative test in the S3 (preferred) or S4 foramen;21 years of age and older;For patients* over 70 years of age, or any patient at the discretion of the Investigator, Edmonton Frail Scale score of 9 or less;Failed conservative therapy and second-line drug therapy and is not a candidate for additional conservative or second-line therapy ;No changes to current regimen of medications that affect bladder function for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires;Willing and capable of providing informed consent;Capable of participating in all testing associated with this clinical investigation
排除标准
- •More than minimal level of stress incontinence or mixed incontinence with stress component likely to confound study outcome. ;Current urinary tract mechanical obstruction (e.g. benign prostatic enlargement or urethral stricture);Interstitial cystitis or bladder pain syndrome as defined by either AUA or EAU guidelines;Chronic pelvic pain;History of any pelvic cancer;Uncontrolled hypertension;Any significant medical condition that is likely to interfere with study procedures, device operation, or likely to confound evaluation of study endpoints (e.g. Crohn*s disease, moderate to severe fibromyalgia, chronic pain, etc.);Any psychiatric or personality disorder at the discretion of the study physician;PHQ-15 score of *15 ;Current symptomatic urinary tract infection (UTI) or more than three (3) UTIs in past year;Any neurological condition that could interfere with normal bladder function, including stroke, epilepsy, multiple sclerosis, Parkinson*s disease, clinically significant peripheral neuropathy, or spinal cord injury (e.g., paraplegia);Uncontrolled diabetes (A1C > 6.5, documented in the last three (3) months) ;Diabetes with peripheral nerve involvement;Treatment of urinary symptoms with botulinum toxin therapy within twelve (12) months prior to SNM implant date;Treatment of urinary symptoms with tibial nerve stimulation within three (3) months prior to SNM implant date;Previously implanted with a sacral neuromodulation device;Underwent an external trial and was deemed a non-responder ;Pelvic organ prolapse stage 3 or higher;History of pelvic floor surgery, including surgical treatment for stress incontinence or prolapse, within 6 months prior to SNM implant date;Surgical treatment for stress incontinence (sling, Burch or urethral injection) or pelvic organ prolapse recommended or planned at enrollment ;History of allergic response to titanium, zirconia, polyurethane, epoxy, or silicone;Knowledge of planned MRIs on areas other than the head, diathermy, or high output ultrasonic exposure;Any other active implanted devices (e.g., drug delivery pumps, pacemaker, ICD) including neurostimulators whether turned on or off. Passive implants (e.g., prostheses) are allowed, but no implanted metal should be at the Neurostimulator implant site;A female who is breastfeeding;A female with a positive urine pregnancy test ;Currently participating in another clinical trial
研究者
相似试验
已完成
不适用
Axonics SacRal NeuromodulaTIon System for Urinary Urgency Incontinence TreatmeNtUrinary Incontinence, UrgeNCT03327948Axonics, Inc.145
已完成
不适用
Sacral Neuromodulation for Neurogenic LUT DysfunctionRefractory Neurogenic LUTDNCT02165774University of Zurich61
招募中
不适用
Sacral Neuromodulation for Male Overactive Bladder (MOAB)Urinary Urgency IncontinenceOveractive BladderBenign Prostatic HyperplasiaProstate CancerOveractive BladderBenign Prostatic HyperplasiaNCT06511141Axonics, Inc.150
已完成
不适用
Subsensory sacral neuromodulation for incontinenceFaecal incontinenceDigestive SystemISRCTN98760715Queen Mary University of London39
终止
不适用
The Effects of Sacral Neuromodulation for Urinary Urgency, Frequency, and Urge IncontinenceUrinary Urge IncontinenceNCT02776475TriHealth Inc.18